We then anticipate filing the Biologics License Application for a biosimilar and interchangeable insulin glargine to Sanofi's Lantus Solostar in the spring of 2023 and potentially launching the ...

They say these specific medications – dulaglutide (Trulicity), insulin glargine (Lantus Solostar, Toujeo Solostar), and insulin lispro (Admelog Solostar) – are available now.

Biocon Biologics said that the US Court of Appeals for the Federal Circuit upheld the US Patent and Trademark Appeal Board's decisions for unpatentability of five device patents for Sanofi's Lantus ...

Shreehas Tambe, CEO, Biocon Biologics, said: "The decision of the U.S. federal court in favour of our partner Viatris, on all the five Sanofi Lantus SoloSTAR device patents is a vindication of our ...

Sanofi sells the product in vials [Lantus] and as a disposable injection pen [Lantus SoloSTAR]. The Semglee products are available in vial and prefilled pen presentations and are interchangeable for ...

Biocon Biologics in a tweet said, "#BioconBiologics Partner Viatris Wins U.S. Court Decisions on all the five Sanofi Lantus® SoloSTAR® device patents.

Sanofi had appealed against all these PTAB decisions to USCAFC. "The decision of the US federal court in favour of our partner Viatris, on all the five Sanofi Lantus SoloSTAR device patents is a ...

Viatris wins US court decision on Sanofi’s appeals for Lantus patents invalidation Sanofi had appealed against all PTAB decisions that found the challenged claims unpatentable in April and May ...

Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin injection pen in a victory for drugmaker Viatris Inc. A review board was correct to invalidate five ...